UNITY 1: A Study of an Investigational Treatment Regimen of Daclatasvir (DCV) + Asunaprevir (ASV) + BMS-791325 in a Fixed Dose Combination (the DCV 3DAA (Direct Acting Antiviral) Regimen) for 12 Weeks for the Treatment of Chronic Hepatitis C Virus (HCV) Genotype 1 Infection in Non-cirrhotic Subjects
Clinical trial NCT01979939 · COMPLETED
Trial details
- NCT number
- NCT01979939
- Sponsor
- Bristol-Myers Squibb
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2013-12-01
- Primary completion
- 2014-08-01
- Enrollment
- 416
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.